The global cancer immunotherapy market, valued at USD 134.40 billion in 2024, is expected to grow to USD 148.73 billion in 2025 and USD 346.63 billion by 2035, anticipated to grow at a CAGR of 8.8% during the forecast period. A recent study published in National Institute of Health, in 2025, around 2,041,910 new cancer cases and nearly 618,120 cancer deaths are projected to occur in the US. In December 2024, AstraZeneca Imfinzi

The global non-muscle invasive bladder cancer market, valued at USD 2.92 billion in 2024, is projected to reach USD 3.47 billion in 2025 and USD 14.01 billion by 2035, representing a CAGR of 15.0% during the forecast period. Non-muscle invasive bladder cancer (NMIBC) is a form of early-stage cancer that remains confined to the inner linings of the bladder. Recently, there has been a surge in the cases of non-muscle invasive bladder cancer among the population worldwide. A recent report by ACS es...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Neuromyelitis optica. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the drug

This report provides an informed opinion on the likely adoption of therapeutics designed to treat peanut allergy. It features an in-depth analysis, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape and its growth prospects over the coming years, providing information about the product

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. Notably, a high therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy. With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time...

The PARP inhibitors market is estimated to be worth $8 billion in 2030 and is expected to grow at CAGR of 18% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. According to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. Therefore, there is a pressing need for more specific and poten...

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for 2 or 3 different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. As of now, only 2 bsAbs, Removab and Blincyt...

The global immune checkpoint inhibitors market is likely to be worth $25 billion by 2025. It is worth mentioning that recently, the focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

Targeted cancer therapy is an upcoming area gaining strong foothold in the industry and has already become the focus of a number of pharmaceutical companies. Small molecule protein kinase inhibitors are a type of targeted therapy that involves small molecule drugs administered in the cancer patient for specifically targeting certain proteins, called kinases, involved in the growth of cancer cells. In fact, non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Ther...

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). However, the high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. Notably, there are specific opportunities which remain to be tapped in...